Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Mbx-8025 Lysine
2. Seladelpar Lysine Dihydrate
3. Mbx-8025 Lysine Dihydrate
4. 928821-40-3
5. Seladelpar Lysine [usan]
6. Mbx-8025 Lysine Salt, Dihydrate
7. N1429130kr
8. Seladelpar (lysine Dihydrate)
9. Unii-n1429130kr
10. Seladelpar Lysine (usan)
11. Chembl3989960
12. Wtkswpygzdcunq-jzxfcxspsa-n
13. Hy-19522c
14. Akos040747473
15. Cs-1068545
16. D11257
17. Q27284370
18. (2s)-2,6-diaminohexanoic Acid;2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic Acid;dihydrate
19. (r)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic Acid Compound With (s)-2,6-diaminohexanoic Acid Dihydrate
20. L-lysine (4-(((2r)-2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)sulfanyl)-2-methylphenoxy)acetate Dihydrate
21. L-lysine, 2-(4-(((2r)-2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetate, Hydrate (1:1:2)
1. 851528-79-5
2. Mbx-8025
3. Mbx-8025 (seladelpar)
4. Seladelpar
| Molecular Weight | 626.7 g/mol |
|---|---|
| Molecular Formula | C27H41F3N2O9S |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 16 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 182 |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 617 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
Drugs in Development
Details:
The partnership aims for the distribution of a novel selective, first-in-class, PPAR delta agonist, Livdelzi (seladelpar), to treat adults with primary biliary cholangitis (PBC).
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livdelzi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 16, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Partnership
PANTHERx® Rare Partnering with Gilead Sciences, Inc. for the Distribution of LIVDELZI®
Details : The partnership aims for the distribution of a novel selective, first-in-class, PPAR delta agonist, Livdelzi (seladelpar), to treat adults with primary biliary cholangitis (PBC).
Brand Name : Livdelzi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 16, 2024
Details:
Livdelzi (seladelpar) is a novel selective, first-in-class, PPAR delta agonist, indicated to treat adults with primary biliary cholangitis (PBC).
Lead Product(s): Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livdelzi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2024
Lead Product(s) : Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
With FDA Approval of Livdelzi, Gilead Launches an Inflammatory Drug for The First Time
Details : Livdelzi (seladelpar) is a novel selective, first-in-class, PPAR delta agonist, indicated to treat adults with primary biliary cholangitis (PBC).
Brand Name : Livdelzi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2024
Details:
Gilead will buy out Johnson & Johnson’s global royalties for primary biliary cholangitis drug Livdelzi (seladelpar lysine), a peroxisome proliferator-activated receptor (PPAR)-delta agonist.
Lead Product(s): Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livdelzi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Gilead
Deal Size: $320.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 08, 2024
Lead Product(s) : Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Gilead
Deal Size : $320.0 million
Deal Type : Licensing Agreement
Gilead shells out $320M to J&J to buy out rare liver disease drug royalties
Details : Gilead will buy out Johnson & Johnson’s global royalties for primary biliary cholangitis drug Livdelzi (seladelpar lysine), a peroxisome proliferator-activated receptor (PPAR)-delta agonist.
Brand Name : Livdelzi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 08, 2024
Details:
MBX-8025 (seladelpar) is an investigational first-in-class oral, selective PPAR delta agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gilead’s Seladelpar Shows Sustained Efficacy and Safety Profile in PBC
Details : MBX-8025 (seladelpar) is an investigational first-in-class oral, selective PPAR delta agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2024
Details:
MBX-8025 (seladelpar) is a first-in-class oral, selective peroxisome proliferator-activated receptor delta agonist being evaluated for treating primary biliary cholangitis.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Seladelpar Shows Liver, Itch Improvements in PBC
Details : MBX-8025 (seladelpar) is a first-in-class oral, selective peroxisome proliferator-activated receptor delta agonist being evaluated for treating primary biliary cholangitis.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2024
Details:
Gilead expands its liver portfolio by acquiring CymaBay’s MBX-8025 (seladelpar), a PPARδ agonist for treating primary biliary cholangitis (PBC) and associated pruritus.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Gilead Sciences
Deal Size: $4,300.0 million Upfront Cash: $4,300.0 million
Deal Type: Acquisition March 22, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : $4,300.0 million
Deal Type : Acquisition
Gilead Sciences Announces Completion of Acquisition of CymaBay
Details : Gilead expands its liver portfolio by acquiring CymaBay’s MBX-8025 (seladelpar), a PPARδ agonist for treating primary biliary cholangitis (PBC) and associated pruritus.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : $4,300.0 million
March 22, 2024
Details:
MBX-8025 (seladelpar) is an investigational first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for Primary Biliary Cholangitis.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CymaBay's Seladelpar MAA Accepted by EMA for Primary Biliary Cholangitis
Details : MBX-8025 (seladelpar) is an investigational first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for Primary Biliary Cholangitis.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2024
Details:
Gilead expands its liver portfolio with CymaBay’s MBX-8025 (seladelpar), a PPARδ agonist for primary biliary cholangitis.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Gilead Sciences
Deal Size: $4,300.0 million Upfront Cash: $4,300.0 million
Deal Type: Acquisition February 12, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : $4,300.0 million
Deal Type : Acquisition
Gilead Sciences Expands Liver Portfolio with Acquisition of CymaBay Therapeutics
Details : Gilead expands its liver portfolio with CymaBay’s MBX-8025 (seladelpar), a PPARδ agonist for primary biliary cholangitis.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : $4,300.0 million
February 12, 2024
Details:
MBX-8025 (seladelpar) is an investigational first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for Primary Biliary Cholangitis.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CymaBay’s Seladelpar NDA for Primary Biliary Cholangitis Accepted By FDA
Details : MBX-8025 (seladelpar) is an investigational first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for Primary Biliary Cholangitis.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 12, 2024
Details:
MBX-8025 (seladelpar) is an investigational treatment for people with PBC, is a first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): Seladelpar Lysine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MBX-8025
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Lead Product(s) : Seladelpar Lysine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MBX-8025 (seladelpar) is an investigational treatment for people with PBC, is a first-in-class oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of Primary Biliary Cholangitis.
Brand Name : MBX-8025
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
